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ABSTRACT

The ability of the indirect dopamine agonist, amphetamine,
to produce behavioral sensitization was assessed in adult

DiA-deficient and wild-type mice.

It was originally

predicted that: 1) dopamine (DA) Di-like receptors are
necessary for the occurrence of short- and long-term

amphetamine-induced behavioral sensitization, 2) DA Di-like
receptors are necessary for environmental conditioning
factors associated with amphetamine-induced behavioral
sensitization, and 3) DA D5 receptors are required for
amphetamine-induced behavioral sensitization.

Locomotor

activity and stereotyped sniffing were assessed in each of
three experiments.

In Experiment 1, adult wild-type and DiA-deficient mice
were injected with amphetamine (1.0, 2.0, 4.0, or 8.0

mg/kg, i.p.) or saline for seven consecutive days and then
challenged with amphetamine after three and seventeen
abstinence days.

In Experiment 2, wild-type and Dia

deficient mice were injected with amphetamine (8.0 mg/kg,
i.p.) or saline in either their home cage or testing
chamber for seven consecutive days.

Mice were then

challenged with amphetamine (1.0 mg/kg, i.p.) after three
abstinence days to determine whether the Dia receptor is

iii

necessary for the environmental conditioning factors
associated with amphetamine-induced behavioral

sensitization.

After an additional day, all mice were

challenged with saline to determine the influence of the Dia

receptor on conditioned activity.

In Experiment 3, wild-

type and DiA-deficient mice were co-administered the DA Di-

like antagonist SCH-23390 (0.15, 0.50, or 1.5 mg/kg, i.p.)
and either amphetamine (8.0 mg/kg, i.p.) or saline for
seven consecutive days.

Mice were then challenged with

amphetamine (1.0 mg/kg, i.p.) in the testing chamber after
three abstinence days to determine whether the D5 receptor
is important for amphetamine-induced behavioral
sensitization.

The results of the first experiment showed that the

DiA-receptor is not necessary,for short- and long-term
amphetamine-induced behavioral sensitization.

In the

second experiment, DiA-deficient mice were not found to be

heavily influenced by drug-paired cues (Pavlovian

associations), but they did show pronounced conditioned
activity when compared to wild-type controls.

Results from

the third experiment determined that the Di-like receptor is
necessary for amphetamine-induced behavioral sensitization

in wild-type mice, but that neither Dia nor D5 receptors are

iv

required for amphetamine-induced behavioral sensitization
in DiA-deficient mice.

When taken together, these results

indicate that DiA-deficient and wild-type mice are both able

to express amphetamine-induced behaviora1 sensitization.

Wild-type mice require the Di-like receptpr to express
amphetamine-induced behavioral sensitization, whereas Dia
deficient mice apparently developed a compensatory

mechanism which enables them to express amphetamine-induced
behavioral sensitization independent of both Dia and D5

receptors.

The nature of this compensatory mechanism is

not yet understood.

ACKNOWLEDGMENTS,

"

I would like to thank Sanders McDougall, CYnthia
Crawford, and Jeffrey Thompsdh for taking the time to^^

participate as committee members throughout;the completion
of my thesis.

I would like to extend my thanks to Cynthia Crawford

for allowing me to have the opportunity to work with a

distinct animal population, making this work possible.
I would also like to thank Mia, Arbi, Eva and Audrey

for helping me complete this long and arduous undertaking.
Your time and support was appreciated.

,

Special thanks are extended to Sanders McDougall.

You

have given me the tools to be a successful person in a
field for which I truly love

Thanks for giving me the

strength to believe in myself, and the determination to see

a job through.

Although I put myself in a difficult

position in seeing this work through, you knew how to keep
me focused and attentive.

I am truly grateful for your

I would like to say thanks to my family and friends ,

for your encouragement and support.

VI

I will miss you all.

TABLE OF CONTENT'S

ABSTRACT

iii

ACKNOWLEDGMENTS

vi

TABLE OF CONTENTS

vii

LIST OF FIGURES

X

INTRODUCTION

Dopamine Pathways and Input/Output Structures.....

1

Mesolimbic Dopamine Pathway

2

Evidence Indicating That Psychostimulant Drugs
Affect the Mesolimbic Dopamine Pathway

4

Nigrostriatal Dopamine Pathway

5

Evidence Indicating That Psychostimulant Drugs
Affect the Nigrostriatal Dopamine Pathway

5

Dopamine Receptor Classification

8

Brain Structures Associated With Di-Like and

D2-Like Receptor Mediated Behaviors

10

Dopamine Df-Like and D2-Like Receptor
Interaction

12

Amphetamine and Sensitization

15

Sensitization in Terms of Associative Learning
(Environmental Conditioning)

16

Conditioning Factors (i.e., Pavlovian
Associations)in Amphetamine Sensitization

20

The Involvement of Excitatory Amino Acids in
Behavioral Sensitization: A Neural Basis of
Behavioral Sensitization

................

The Involvement of Dopamine Di-Like Receptors

Vll

23

in Behavioral Sensitization: A Neural Basis of
Behavioral Sensitization.

......

25

Dopamine D5 Receptor Subtype in Amphetamine
Sensitization

28

Genetic Tools For Studying Receptor Function.......

29

Summary.

29

Hypothesis....

......

Experimental Plan.

30
31

GENERAL METHOD

Subjects..........

...

33

Apparatus.

33

Drugs

34

Statistical Analysis

34

General Procedure..

34

Genotyping

35

EXPERIMENT 1

Method.

. /........

38

Results.

39

, Summary...,.....
EXPERIMENT 2

.

.

.

Method.

.....

Results

50

... ......................

52

.1...................

58

Summary.
EXPERIMENT 3

48

,

viii

Method

.t.....

Results.:.

..

. 62

Summary..................
DISCUSSION........

61

76
...1 ...........■

....

77

DA Dia Receptor Involvement in Amphetamine
Sensitization

81

DA Ds Involvement in Amphetamine-Induced Locomotor
Sensitization......................

82

The Influence of Compensatory Mechanisms in Dia
,Deficient Mice

84

D2^Like Receptor involvement in Plasticity

85

Conditioned Activity in Wild-Type and DiaDeficient Mice........ ................ ....

.

85

Di-Like Receptor Antagonism: Behavioral Evidence
for Receptor Upregulation or Supersensitivity......

86

The Role of Dynorphin in DiA-Deficient
Mice.......

Summary.
REFERENCES...... .. ...

87

^

90
•„>

IX

92

LIST OF FIGURES

Figure 1

Mesolitnbic Dopamine Pathway.

DYN =

Dynorphin; DA = Dopamine; k = K-Opioid
receptors; GABA = y-Amino Butyric Acid; EAA
= Excitatory Amino Acid
Figure 2

Figure 3

Nigrostriatal Dopamine Pathway. DYN
Dynorphin; DA = Dopamine; K = K-Opioid
receptors; GABA = y-Amino Butyric Acid.
Mean distance traveled (±SEM) of adult wild-

type and Dia-deficient mice (n = 6 - 10 per
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pretreatment days. Behavioral assessment
lasted for 60 min and occurred immediately

after injection. O = SAL; 0 = 1.0 mg/kg
AMPH; ♦ = 2.0 mg/kg AMPH; A = 4.0 mg/kg
AMPH; ■ = 8.0 mg/kg AMPH. * Significantly
different from the SAL group (p < .05)
Figure 4
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adult wild-type and DiA-deficient mice (n = 6
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type and DiA-deficient mice (n = 7 - 8 per
group) during testing (these are the same
mice as in Figures 1 and 2). Mice had
previously received seven consecutive
injections of saline (SAL) or amphetamine
(AMPH; 1.0, 2.0, 4.0-, or 8.0 mg/kg, i.p.).
After 3 abstinence days all mice received a
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second injection. * Significantly
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INTRODUCTION.

, It is now weli estabiished that dopam

(DA) has

intimate ties with the basic underlying neurobiological
mechanisms of drug,,, addiction. TTn .faGt, the DA^^

, :

neurotransmitter system n^^ . only mediates 'reward., but. also
the locomotor activating effects of various drugs of abuse.

Several studies suggest that DA is the main
neurotransmitter associated with reward and reinforced

:

■

responding (Kalivas & Stewart, 1991; Nestler, 1992;
Robinson & Becker, 1986; Robinson & Berridge, 1993; Wise &

.Bozarth, 1984). For example, various psychostimulants, such

as cocaine and amphetamine, augment locomotor activity and

reward by indirectly increasing DA concentrations in the

synapse (Reith, Sershen, & Lajtha, 1980). This increase in'
, DA has been shown to exert a euphoric-like effect, as well
as induce other motivational factors associated with drug

craving (Robinson & Berridge, 1993); and, consequently, , , ;

psychostimulants are subject to abuse (Robinson & Berridge,
,1993; Wise .fc/Bozarth,: 1987).

Dopamine Pathways and Input/Output Structures

Psychostimulant drugs, like amphetamine and cocaine,
increase DA in the synapse by either blocking or reversing
the DA reuptake pump.

More specifically, cocaine

indirectlY augments DA levels by blocking the DA reuptake
pump, therefore enabling synaptic DA to persist in the
synapse longer (Relth et al., 1980). Amphetamine reverses

the reuptake pump, thus transporting newly synthesized;, DA
into the synapse (Seiden, Sabbl, & Ricuarte, 1993).

As key

■

systems regulatihg reward and behavioral activity, the
mesolimbic and nigrostriatal DA pathways appear to be

primary sites of action for psychostimulant drugs. (Wise &
Bozarth,. 1984).

.) /

Mesolimbic Dopamine Pathway

,

The mesolimbic DA pathway is comprised of cell bodies

in the ventral tegmental area which have axons that project
from this midbrain structure to an area in the forebrain,

known as the striatiim (see Figure 1) (Pierce & Kalivas,

1997; Wise & Bozarth, 1987).

The most anterior portion of

the Striatum is a structure commonly referred to as the
nucleus accumbens (or ventral striatum). Fibers which ;

originate in the ventral tegmental area and terminate in
the nucleus accumbens modulate GABA-ergic efferefits .

'

projecting to the prefrontal cortex and substantia nigra
(Bedingfield, Calder, Thai., & Karler,, ,1997; Karler,

Bedingfield, Thai," & Calder, 199.7; Pierce & Kalivas, 1997; ;
Smith & Bolam, 1990). Psychostimulant-induced modulation of

DA
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Figure 1.

Mesolimbic Dopamine Pathway.

Excitatory Amino Acid.

the mesolimbic DA tract has been theorized to mediate

behavioral (i.e., locomotor) activity and the subjective
effects of reward (Wise & Bozarth, 1987).

Evidence Indicating That Psychostimulant Drugs Affect the
Mesolimbic Dopamine Pathway

DA receptors in the nucleus accumbens are stimulated

by psychostimulant drugs through two mechanisms (Bjijou,
Stinus, Le Moal, & Cador, 1995); Vezina, 1993; 1996).
First, intra-cranial infusion of amphetamine into the

ventral tegmental area produces an augmented concentration
of DA in the nucleus accumbens (Vezina, 1993; 1996).

Second, microinjecting cocaine or amphetamine into the
nucleus accumbens produces robust behavioral activity by
indirectly increasing DA levels (Delfs, Schreiber, &
Kelley, 1990). Lesioning the nucleus accumbens
substantially reduces behavioral activity induced by

systemic amphetamine injections (Kelly & Iversen, 1976).
Since psychostimulant drugs have a high abuse

potential in humans (Di Chiara, 1998; Robinson & Berridge,
1993) it is not surprising that intravenous self-

administration of psychostimulant drugs has been intensely
studied in animals. To this end, animals will readily self-

administer amphetamine or cocaine directly into the nucleus

accumbens or the ventral tegmental area (Collins, Weeks,

Cooper, Good, & Russell, 1984; Schuster & Thompson, 1969).
When the mesolimbic DA system is lesioned by 6

hydroxydppamine (6-OHDA) or kainic acid, self
adminisbration of cocaine (Pettit, Rttenberg/ Bloom,- & '
Koob, 1984; Roberts, Koob, Klonoff, & Fibiger, 1980) or

amphetamine (Lyness, Friedle, & Moore, 1979) is abolished.
Clearly then, DA receptor stimulation in the mesolimbic
pathway mediates cocaine and amphetamine selfadministration.

Nigrostriatal Dppamine;Pathway

(C ; /A

opposed to the mesolimbic DA pathway, the

nigrostriatal DA pathway primarily mediates behavioral
stereotypy (Arnt, 1987). The nigrostriatal DA pathway

includes two primary brain areas: the substantia nigra and
the caudate/putamen (also called the dorsal striatum; see

Figure 2).

Specifically, DA neurons project from the

substantia nigra to the caudate/putamen; Clark & White,
1987; Pierce & Kalivas, 1997).

Accordingly then, DA

receptors in the caudate/putamen are indirectly stimulated
by psychostimulant drugs and, as a result, cause behavioral
stereotypy.

Evidence Indicating That Psychostimulant Drugs Affect the

Caudate/Putamen
(Dorsal Striatum)
DA DA

DAD

DA Receptors

DA
GABA . &

Neuron

Dynorphin
N1grostri:ata1
Pathway

Str1atonigra1

Neuron

Pathway

K-Opidid
receptors

/

on

/dendrites

Substantia Nigra
To Thalamus

Figure 2. Nigrostriatal bopamine Pathway. DYN = Dynorphin; DA
Dopamine; K = K-Opioid receptors; GABA = y-Amino Butyric Acid.

Nigrostriatal Dopamine Pathway

DA receptors in the caudate/putamen are indirectly
stimulated by psychostimulant drugs (Dickson, Lang, Hinton,

& Kelly 1994; Statoni Solomon, 1984).

Systemic

,administration of lower doses of amphetamine preferentially
induces locomotor activity, presumably because of increased
DA receptor stimulation in the nucleus accumbens.

In

contrast, systemic administration of higher doses of

amphetamine produces stereotyped behaviors via stimulation

of the caudate/putamen (Clark & White, 1987; Sharp,
Zetterstrom, Ljungberg, & Ungerstedt, 1987).

In fact,

microinjecting amphetamine into the caudate/putamen induces
intense oral stereotypies, consisting of bar biting, noninjurious self-biting and repetitive paw-to-mouth movements
(Dickson et al., 1994), whereas microinjecting amphetamine
into the nucleus accumbens only produces locomotor activity
(Staton Sc Solomon, 1984).

Similarly, Stahl and colleagues have shown, using

electroencephalograph (EEG) pattern recognition, that
amphetamine affects different brain regions depending on
dose administered (Stahl, Ferger, & Kuschinsky, 1997). In
terms of stereotypy, low versus high doses of amphetamine
cause a shift of activation from the mesolimbic DA system

to the nigrostriatal DA system, respectively (Stahl et al.,
1997),

Additionally, other researchers suggest an additive

relationship between the DA systems.

Chronic amphetamine

treatment produces augmented DA release in the nucleus
accumbens and thereby induces locomotor activity and

rearing (Robinson, Jurson, Bennett, & Bentgen, 1988),
whereas the same chronic treatment produces augmented DA

release in the caudate/putamen, resulting in intense oral

stereotypies (Kelly, Seviour, & Iversen, 1975; Patrick,
Thompson, Walker, & Patrick, 1991).
Dopamine Receptor Classification

As study of the DA neurotransmitter system progressed,
the initial classification of DA receptors was revised to
include a number of DA receptors subtypes. Generally, DA.

receptors belong to a class of seven-transmembrane domain,
G-protein-coupled receptors (Seeman & Van Tol, 1994;
Sokoloff & Schwartz, 1995).

Based on sequence homology

studies, six DA receptors have been cloned: Dia, D2S/ D2l/ D3,

D4, and D5 (D5 is sometimes referred to as Dib) (Seeman & Van
Tol, 1994; Sokoloff & Schwartz, 1995).

These receptors can

be separated into two subfamilies, Di-like and D2-like,
based on the original biochemical classification of
Kebabian and Calne (1979).

The Di-like receptor family

includes the Di and D5 receptors, whereas the D2 family
includes the Das/ D2L/ D3, and D4 receptors (Clark & White,
1987).

As the importance of these subtypes became known,

pharmacological.compounds for these DA receptor subtypes
were developed.

Using selective DA agonists and

antagonists, a number of receptor-specific behavioral
profiles have been determined.

For example, Di-like

receptor stimulation dramatically augments grooming,
rearing, and non-stereotyped locomotor activity, yet has

little effect on yawnihg and, sniffing (Arnt, 1987; Braun &

Chase, 1986; Molloy & Wadding;ton, 1987). On the other hand,
D2-like receptor activation produces stereotyped locomotor
activity, yawning and sniffing; (Arnt, 1987,; Johansspn,

:

Levin, Gunne, & Ellison, 1987; Longoni, Spina, & Di Chiara,

1987; White) Bednarzi

IJjoith, &,Broocierson, ; l988);i

In addition, Di-like receptor stimulation by SKF-38393 (a

Di-like receptor agonist) induces lodomot

activity, while quinpirole-induced stimulation of Ds^like
receptors produces only stereotyped locomotor activity and

sniffing (Page & Terry, 1997; Hooks et ai., 1994:)- Systemic
injections of I^-propylyorapomorphine (NBA; a full dopamine

receptor agonist) induce, robust stereotypy with minimal,

loCoraotor activity■ (Bordi, Carr, & Meller> i989) .
Logically then, Clark and White'' f(1987) hypothesized that Dilike receptors mediate low-intensity behaviors, but '

t,'

hypothesized that high-intehsity behaviors require the coactivation of both Di-like and D2-like receptors.
Other studies indicate that tonic activation of Di-like

receptors is essential for the full behavioral expression
of Da-like receptor mediated behaviors.

Accordingly, Molloy

and Waddington (1987) have shown that antagonizing Di-like
receptors with SCH-23390 attenuates Dalike agonist-induced
locomotion.

Di-like receptor-mediated behaviors, on the

other hand, do not need co-activation of Da-like receptors

(White et al. , 1988) .

To affirm this. Da-like receptor

blockade failed to influence Di-like receptor-mediated

behaviors, perhaps indicating a one-way synergistic role

between the Di and Da receptor families (White et al. ,
1988) .

1' '' '

^ ^ '•1

Brain Structures Associated With Dj-Like and Da^Like; , ,
Receptor-Mediated Behaviors

Although stimulation of DA receptors induces a wide

range of behaviors, several DA receptor-specific behaviors
have been linked to particular brain areas.

As such, Di

like, receptor-mediated behaviors, (grdoming, rearing:: and
locomotor activity) are thought to be induced via
stimulation of .the nucleus accumbens, while D2-like

receptor-mediated behaviors (stereotyped sniffing and
yawning) are thought to be primarily induced through
■stimulation of the caudate/putamen (Bordi et al. , 1989;
Deifs et al. , 1990; Dickson et al. , 1994; Staton & Solomon,

'198,4) . ■ .vi-

y;

,

Psychostimulant drugs induce many of the same
behaviors that are produced by DA Di-like- and. D2-like

receptor agonist drugs.

In fact, low doses of amphetamine

elicit locomotor activity and sniffing, whereas higher
doses tend to reduce locomotor activity while promoting
intense oral stereotypies (Kelly, Sevipur, & Iversen,

1975) . As a result, amphetamine displays a broad behavioral

profile, as it can produce different intensities of

.

behavior in a dose-dependent manner (Dickson et al. , 1994) .
', Through EEG pattern recognition, Ferger, Kropf, and

Kuschinsky (1994) revealed that cocaine and amphetamine
preferentially affect Di-like receptors. Thus acute
treatment with low doses of amphetamine produce EEG

patterns precisely resembling Di-like receptor agonist EEG

patterns, suggesting mesolimbic DA system activity.

■
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After

repeated amphetamine injections, or after an acute
injection with a high dose of amphetamine, both Di-like and

D2-like receptor EEG patterns were evident, suggesting a
synergistic relationship between mesolimbic and
nigrostriatal systems. These results are consistent with
other studies showing that low doses of amphetamine and

cocaine produce low-intensity behaviors, such as locomotor

activity and rearing (a Di-like effect), whereas high doses
produce high-intensity behaviors, such as oral stereotypies
(a combined Di-like and D2-like effect; Clark & White, 1987;

White et al., 1988)-. What is more, Di-like receptor EEG

patterns were fully attenuated by the DA Di-like receptor
antagonist SCH-23390, while D2-like EEG patterns were only
reduced (Stahl et al., 1997).

Dopamine Dj-Like and D2-Like Receptor Interaction

Research suggesting a synergistic interaction between
DA Di-like and D2-like receptors implies that stimulation of

Di-like receptors somehow 'facilitates' or 'enables' D2-like

,receptor-mediated behaviors. Because amphetamine can
produce intense stereotypy at high doses (Callaway,
Kuczenski, & Segal, 1989; Clark & White, 1987), amphetamine
must also stimulate DA D2-like receptors, albeit indirectly.
This conclusion is not surprising.

12

In point of fact, both

spiperone : and sulpiride (Os^like,,reGeptor. antagoiaists) block
amphetamine-induced stereotypy, but leave locomotor

activity relatively unaffected. This indicates that the Da
like receptor is necessary for amphetamine-induced
stereotypy (Bedingfield et al., 1997).
The potent and specific Da-like receptor agonist,

quinpirole, induces a wide range of behaviors, like
locomotor activity, sniffing and yawning (Dall'Olio,
Gandolfi, Vaccheri, Roncada,. & Montanaro, 1988; Longoni et

al., 1987; Molloy & Waddington, 1987).

Quinpirole-induced

behaviors are intensified by the Di-like receptor agonist,
SKF-38393, converting normal Da-like receptor-mediated
behaviors to more intense and focused forms of stereotypy

(licking and gnawing) (Dall'Olio et al., 1988; Starr, 1988;

White et al., 1988). In fact, after systemic DA depletion

by a-methyl-p-tyrosine (AMPT; a tyrosine hydroxylase
inhibitor), quinpirole-induced behaviors are abolished, yet
the same behaviors are reinstated when SKF-38393 is

administered (White et al., 1988).

The reciprocal

relationship, however, does not exist, as quinpirole fails
to alter SKF-38393-induced grooming, further indicating
that Di-like receptor stimulation enables D2-like receptor
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mediated behavior (white et al., 1988).

Other neurotransmitter systems (e.g., excitatory amino

acids and GABA) modulate amphetamine-induced behaviors.

That is, CPP (an NMDA receptor antagonist) and THIP (a GABAa
receptor agonist) attenuate amphetamine-induced stereotypy
(Karler et al., 1997).

Not surprisingly, NMDA and GABAa

receptors are co-expressed on nigrostriatal and
striatonigral DA neurons, suggesting that the mechanisms

mediating amphetamine-induced stereotypy are much more
complex than originally thought (Karler, Calder, ChaUdhry,
Sc Turkanis, 1989; Karler, Calder, & Tiirkanis, 1991; Pierce.
Sc Kalivas, 1997; Wolf & Jeziorski, 1993).

In sum, chronic treatment with psychostimulant drugs

has been shown to alter dopaminergic, GABA-ergic, and
glutaminergic systems (Cador, Bjijou, Cailhol, & Stinus,
1999; Vezina, 1993; Vezina & Stewart, 1989; Wolf, 1998).

Because these neurotransmitter systems are involved in drug
craving, addiction, and reward, the impact of chronic

amphetamine treatment on these systems has been intensely
investigated.

As a result, over the past decade, several

theories describing psychostimulant abuse have been
developed, most of them focusing on the effects of chronic
amphetamine treatment.

■

■
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Amphetamine and Sensitization

Chronic amphetamine use in humans can result in twp

major disorders: drug addiction and amphetamine-induced

psychosis (Kalivas & Stewart, 1991; Lett, 1989; Robinson &
Becker, 1986; Robinson & Berridge, 1993; Sato, 1986).

The

most studied is drug addiction, as this phenomenon can be

described as a persistent and intense involvement with
stress upon a single behavior pattern, with a minimization
of exclusion of other behavior patterns.

Chronic

amphetamine use can also result in a condition called

amphetamine psychosis, a state similar to paranoid
schizophrenia (Sato, 1986).

Although the symptoms of

amphetamine psychosis often disappear after cessation of
drug taking, craving for the;drug and hypersensitivity to
the psychomimetic effects remain for years (Robinson &
Berridge, 1993; Sato, 1986).
in animal research, a similar phenomenon is termed
behavioral sensitization, and it occurs after chronic

treatment with amphetamine, cocaine, methylphenidate
(Ritalin), methamphetamine and many other psychostimulant

drugs (Akimoto, Hamamura, Kazahaya, Akiyama, & Otsuki,
1990; Crawford, McDougall, Meier, Collins, & Watson, 1998;

Kalivas & Duffy, 1990; McDougall, Collins, Karper, Watson,
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&: Crawford, 1999; Parsons & Justice, 1993; Patrick et al.,

1991; Pettit, Pan, Parsons, & Justice, 1990; Wolf, White,
NasSar, Broods

& Khansa, 1993).

Behavioral

sensitizatidn is characterized by a progressive and

enduring enhancement of drug-induced behavioral effects of
psychostimulant compounds (Kalivas & Stewart, 1991;

Robinson & Becksr, 1986; Robinson & Berridge,,^^^^^^^l^^^^^
specifically, senSitization is viewed ias tho i

series

of behavioral responses that may lead to drug addiction
(Robinson & Berridge, 1993).

Accordingly, sensitization

has often been depicted as a major component to the animal

model of drug addiction, since it has been shown to persist

for up to a year after a single drug administration
(Paulson, Camp, & Robinson, 1991).

Because sensitization

has similar characteristics to that of paranoid

schizophrenia and the initial stages of drug addiction, a
better understanding of the processes involved would prove
beneficial (Kalivas & Stewart, 1991; Robinson & Becker,

1986; Robinson & Berridge, 1993).
Sensitization in Terms of Associative Learning

(Environmental Conditioning)

Robinson and Berridge (1993) suggests an Incentive-

Sensitization Theory of drug addiction to explain: (1) the
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intense craving and compulsive drug-seeking behavior or

^wanting' of the drug, ad opposed to: 'liking' the drug, (2)
why drug craving often persists, and can be reinstated,

long after the discontinuation of drug use, and (3) why
drug addicts continue to use and 'want' psychostimulant
drugs, despite the decreasing pleasurable effects

experienced after repeated use (Robinson & Berridge, 1993).
The term 'incentive' suggests that while taking
psychostimulant drugs, certain stimuli associated with the
drug-taking environment become salient and induce a
psychological process called 'incentive-salience'.

Thus

stimuli (e.g., rooms, paraphernalia, friends, smells, etc.)
that are continuously, contiguously, and frequently
associated with drug-taking become attractive to the user
and, therefore, psychologically induce 'craving' and

:

'wanting' for the drug (Kozlowski & Wilkinson, 1987;

Robinson & Berridge, 1993). These powerful incentive
stimuli, in turn, create an uncontrollable craving and

wanting for the drug, spawning repeated use that may
develop into drug addiction (Robinson & Berridge, 1993;
Wise, 1988). In essence, the drug-paired environment

produces a psychological incentive to take more drug.
The Incentive-Sensitization theory indicates that

■

■ ■■ - ■
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repeated bouts of drug-taking produce incremental

nduroadaptations in the mesolimbic DA system, rendering it,
perhaps, permanently hypersensitive (sensitized) to these
drug-associated stimuli (Robinson & Becker, 1986; Robinson
& Berridge,^ 1993). Therefore,: drug;-associated stimuli are

(perhaps') permanently destined, via these neuroadaptations
in the mesolimbic DA system, to induce drug-taking
behaviors (Robinson & Berridge, 1993).
The foundation under which DA sensitization is built

is through the process of associative learning (Robinson &
Berridge, 1993). Specifically, the drug-taking environment
elicits drug-taking behaviors. Gonsequently, the drugassociated stimuli imbue the drug-taker with incentivesalience and therefore make the act of drug-taking
attractive and irresistible to the user.

This theory posits that repeated drug use does not
come from the sensitization of the rewarding effects of the

drug, but from the environmental cues that have become

associated with drug-taking (Robinson & Berridge, 1993).
Granted, psychostimulant drugs produce a euphoric-like
effect (Wise & Bozarth, 1987, Wise & Rompre, 1989), however

this theory makes a clear distinction between 'wanting'
(i.e., craving) and 'liking' (i.e., rewarding) the
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psychostimulant drug (Robinson & Berridge, 1993).
Testimonials of ex-drug abusers reflect this, as they

express a generalized dislike for the drug after extended
use, but they continue to use the drug and risk everything

to obtain the drug, despite the diminishing pleasurable
effects of the drug (Robinson & Berridge, 1993; Sato,

1986). Therefore, drug addiction may not be sustained via
the rewarding characteristics of the drug, but through the

craving and wanting which develop as a result of incentivesalience.

Two Other theories of addiction have tried to explain

the uncontrollable urge to take drugs: the positivereinforcement model and the negative-reinforcement model.

Specifically, the negative-reinforcement model posits that
drugs are taken to avoid the symptoms of withdrawal,
whereas the positive-reinforcement model posits that drugs

are taken for their reinforcing effects (Robinson & Becker,

1986; Robinsdh & Berridgei j; 1993; Wise & Bozarth, 1987, Wise
Sc Rompre, 19S9).

Importahbly, both theories cannot explain

why abusers relapse even after the symptoms of withdrawal
have subsided and after many years of abstinence.
Moreover, neither of these theories can explain why
previous drug abusers continue to crave their specific

■

■
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drug, even though the pleasurable effects of the drug
became attenuated (Stewart, de Wit, & Eikelboom, 1984;

Wise, 1988).

In sum, the incentive-sensitization model clarifies how

these long-term drug effects occur: by the process of
associative learning.

More specifically, with incentive-

salience, the drug-associated stimuli become attractive to
the user and this causes repeated use. Through continuous

drug use specific neuroadaptations occur in the mesolimbic
DA system causing these associations to become permanently
hypersensitive (or sensitized). Therefore, the user craves
drug-associated stimuli, and not the pleasurable effects of
the drugs (as in the positive reinforcement model) or the
avoidance of withdrawal symptoms (as in the negative

reinforcement model). The importance of associative

learning, as suggested by the incentive-sensitization
model, is supported by other research, since environmental
conditions influence the magnitude of sensitization to

psychostimulant compounds (Badiani, Camp, & Robinson, 1997;
Campbell & Raskin, 1978; Mattingly & Gotsick, 1989).
Conditioning Factors (i.e., Pavlovian Associations) in
Amphetamine Sensitization

The neuropharmacological actions of amphetamine and
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cocaine have been well characterized.

These drugs

substantially increase synaptic DA by their action on the

DA transporter (or reuptake pump) (Seiden et al., 1993).
Sensitization to these drugs is a result of increased DA in
the synapse and, from repeated use, produce

neuroadaptations in the neural system where these drugs
have their action.

However, several reports have argued

that behavioral sensitization may develop, not only through

the persistent use of psychostimulant drugs, but also by
associating the drug-taking environment with drug
administration (i.e., Pavlovian Associations) (Anagnostaras
Sc Robinson, 1996; Badiani et al., 1997; Badiani,

Anagnostaras, & Robinson, 1995; Badiani, Browman, &
Robinson, 1995; Campbell & Raskin, 1978; Einat et al.,
1996; Hoffman & Wise, 1992; Lienau & Kuschinsky, 1997;

Mattingly & Gotsick, 1989). For example, recent work by
Robinson and colleagues indicates that the environmental
conditions of the testing chamber alter the acute effects

of amphetamine and the.magnitude of amphetamine and cocaine
sensitization (Badiani, Browman, & Robinson, 1995).

Specifically, if the drug treatment is paired with the
animal's testing environment (but the home cage environment
is different), a greater rate of sensitization would occur
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than if the drug treatment is paired with the home
environment (Anagnostaras & Robinson, 1996; Badiani,
Anagnostaras, & Robinson, 1995; Badiani, Browman, &
Robinson, 1995; Lienau & Kuschinsky, 1997; Mattingly &
Gotsick, 1989).

This would suggest that environmental cues

surrounding the drug treatment have a much stronger
influence on the rate of sensitization than what was

previously thought.

This may be potentially important for

sensitization research and drug addiction, since the

subjective and behavioral effects of addictive drugs

largely depend on the environmental context during drug
administration (Badiani, Browman, & Robinson, 1995; Carlin,

Bakker, Halpern, & Post, 1972; Chait, 1993).
Although environmental conditioning factors may affect
the overall strength of sensitization, these cues only act
in an additive manner.

That is, sensitization still occurs

when environmental cues are eliminated, albeit the
sensitization is not as robust (Badiani, Browman, &

Robinson, 1995).

Thus, the environmental cues work in

tandem with the effects of the psychostimulant drug to
promote craving for the drug (in the human model) or induce
a sensitized increase in behavioral responding (as in the
animal model).
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The Involvement of Excitatory Amino Acids in Behavioral
Sensitization; A Neural Basis of Behavioral Sensitization

Historically, sensitization research has focused on
the idea that changes in the DA system are responsible for
the occurrence of behavioral sensitization (Robinson & ,

Becker, 1986; Robinson & Berridge, 1993; Wise & Bozarth,
1987).

However, recent work has shown that excitatory

amino acids (EAAs) may play an important role in the

development of behavioral sensitization (Wolf, 1998). In
fact, EAAs and DA complement each other in a number of

ways.

That is, EAAs possess a regulatory function over DA,

as antagonism of various EAAs attenuates DA release (KarTer
et al., 1989; 1991).

What is more, several reports suggest

an important role for EAAs in amphetamine- and cocaineinduced behavioral sensitization, as antagonism of specific

EAA subtypes eliminates sensitization to these drugs
(Karler et al., 1989; Wolf & Jeziorski, 1993).

In her theory, Marina Wolf (1998) posited that DA

plays a secondary role to EAAs in behavioral sensitization.
Because EAAs exert a regulatory role over DA, EAAs control

the underlying circuitry responsible for the development of
behavioral sensitization, and therefore make the

involvement of DA less significant than previously thought
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(Wolf, 1998).

This is not to say that DA is not important

for the occurrence of behavioral sensitization, since

behavioral sensitization cannot be produced without the
presence of endogenous DA (Wolf, 1998).

Wolf (1998) provides evidence to support the
involvement of EAA neurotransmitter systems in

sensitization.

Blockade of NMDA receptors by MK-801 (a non

competitive antagonist of the NMDA glutamate receptor)
prevents amphetamine- and cocaine-induced behavioral
sensitization in mice (Karler et al., 1989).

In fact,

blockade of NMDA receptors has also been shown to prevent
Di-like agonist-induced sensitization (Wolf, White, & Hu,

1994).

This evidence clearly supports the involvement of

NMDA receptors in amphetamine-induced behavioral
sensitization.

In addition to NMDA receptors, other glutamate
receptor subtypes are important for amphetamine

sensitization.

For instance, the selective AMPA receptor

antagonist 2,S-dihydroxy-S-nitro-T-sulfamoyl
benzo(f)quinoxalin (DNQX) blocks the development of
sensitization to amphetamine-induced stereotypy and
locomotor activity (Li, Vartanian, White, Xue, & Wolf,
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1997).

In addition, cocaine sensitization was blocked

the AMPA receptor antagonist 6,7 dinitroquinoxaline-2,3
dione (NBQX; Li et al., 1997).

Other AMPA antagonists,

such as 6-CY"ano-7-nitroqinoxaline-2,3-dione (CNQX), block .
expression of cocaine-induced sensitization when
microinjected into the core of the nucleus accumbens

(Pierce, Bell, Duffy, & Kalivas, 1996).
So when this evidence is taken together, EAA and DA
neurotransmitters appear to interact when mediating
behavioral sensitization, since NMDA and AMPA antagonists

block DA agonist-induced behavioral sensitization.
The Involvement of Dopamine Dj-Like Receptors in Behavioral
Sensitization: A Neural Basis of Behavioral Sensitization

In addition to Robinson and Berridge's (1993) and
Wolf's (1998) theories on behavioral sensitization, Vezina

(1996) has developed a theory of behavioral sensitization
that primarily focuses on the importance of the DA Di family

of receptors.

Paul Vezina (1996) showed that behavioral

sensitization to amphetamine can be eliminated by
antagonizing the Di family of receptors with the potent and

specific Di-like receptor antagonist SCH-23390.

According

to Vezina's model, amphetamine causes somatodendritic DA
release in the ventral tegmental area.

This DA stimulates

Di-like receptors located on the presynaptic terminals of

.

EAA and GABA projections synapsing on DA neurons.

Therefore, araphetamine indirectly:ah^

the activation of

mesolimbic DA neurons by modulating GABA and glutamdte
neurotransmission in the ventral tegmental area (Vezina,

1996).:

h-l''

The location and function of DA Di-like receptors

establishes their importance for behavioral sensitization,
because repeatedly microinjecting amphetamine into the

ventral tegmental area: 1) produces a sensitized behavioral

response to a systemic challenge of amphetamine (Vezina,
1996); 2) produces a significant increase in nucleus
accumbens DA when challenged with a systemic injection of

amphetamine (Vezina, 1996); 3) produces a sensitized
behavioral response to a local infusion of amphetamine into
the nucleus accumbens (Kalivas & Duffy, 1993a; 1993b;
Vezina, 1996); and 4) does not induce behavioral
sensitization when co-administered with SCH-23390 (Bjijou

et al., 1996; Pierre & Vezina

Vezina, 1996).

When

taken together, it is clear that amphetamine-induced
locomotor sensitization requires the activation of DA Di-

like receptors, thus supporting Vezina's (1996) theory that
DA Di-like receptor stimulation in the ventral tegmental

area is necessary for the occurrence of amphetamine-induced
behavioral sensitization.

Currently, the DA Di family of receptors has only two .

members: Dia and D5 (or Dib). , As previously indicated,

Vezina (1996) hypothesized that the Di family of receptors
was responsible for the induction of amphetamine-induced

behavioral sensitization.

Recent work on the DA Di family

of receptors has indicated that both Dia and D5 receptors
stimulate adenylyl cyclase activity and have a similar

affinity for SCH-23390 (Baldessarini & Tarazi, 1996; Clark
& White, 1987). But while the Dia receptor may exist in
greater numbers throughout limbic and basal ganglia
circuits, the D5 receptor, when compared to the Dia

receptor, has a much higher affinity for endogenous DA
(Baldessarini & Tarazi, 1996; Kostrzewa, 1995).

The likelihood of a DA D5 influence on amphetamine-

induced behavioral sensitization is plausible, since
repeated administration of psychostimulants has behavioral

impact in DiA-deficient mice.

For example, Crawford, Drago,

Watson, and Levine (1997) showed that amphetamine initiates
less locomotor activity in Dia-deficient mice than wild-type
controls during pretreatment, but DiA-deficient mice still
exhibited a sensitized response when challenged with a low
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dose of amphetamine three days after pretreatment.

DA Dia

deficient mice also show a lessened responsiveness after

acute cocaine trea.tment, as- cocaine-induced hyperactivity
was blunted in mice lacking the DA Dia receptor (Miner,
Drago, Chamberlain, Donovan, & Uhl, 1995; Xu, Hu, Cooper,
Moratalla, Graybiel, White & Tonegawa, 1994).

This is

important since both amphetamine and cocaine function as
indirect DA agonists (Reith et al., 1980).

Therefore,

these data suggest that the DA Dia receptor is necessary for
the induction of amphetamine-induced locomotor
sensitization.

■

Dopamine D5 Receptor Subtype,in Amphetamine Sensitization

The fact that DiA-deficient mice are capable of
expressing locomotor sensitization (Crawford et al., 1997)

suggests that the ■ DA D5 receptor may be importantly involved

in amphetamine-induced sensitization.

Previously, it has

been shown that complete blockade of the DA Di-like receptor
eliminates the occurrence of amphetamine-induced

sensitization (Vezina, 1996) and that serotonergic and DA
D2-like receptor systems are not involved in this

elimination (Bjijou et al., 1996). Therefore, the DA D5
receptor may be critically important for amphetamineinduced behavioral sensitization.

28

Genetic Tools For Studying Receptor Function
Several lines of research establish the importance of

the DA Di-like family of receptors for the occurrence of
Amphetamine sensitization (Bjijou et al., 19967 Grawfordet
al., 19977 Pierre & Vezina, 1998; Vezina, 1996).

Yet

because the DA Di family of receptors includes two different

receptors, it has been impossible to determine the.precise
role that DA Dia and D5 receptors play in amphetamine

sehsitization



Specifically, available ligands are nbt

selective enough to distinguish between the Dia and D5

receptors.:

Fortunately, a DA Dia receptor deficient mouse

was ehgineebed to make the answer to this question more
accessible.

Therefore, the current project will use the

PiA-deficient mouse to assess the importance of DA Dia and D5

receptors for amphetamine-induced behavioral sensitization.
Summary

In general, the results of these studies can be
summarized as follows: 1) Drug addiction involves the DA

system; 2) Psychostimulants such as cocaine and amphetamine
increase DA levels and are often abused; 3) The functioning
of the mesolitnbic and nigrostriatal DA systems is
influenced by psychostimulants; 4) Psychostimulants

indirectly :stimulate DA receptors in the ventral tegmental
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area, which causes augmented DA release in the nucleus

accumbens; 5) Destruction of the mesolimbic DA system,

:

either by lesioning the ventral tegmental area or the
nucleus accumbens, prevents cocaine- and amphetamineinduced locomotor effects; 6) DA Di-like receptor activation

mediates locomotor activity and rearing, whereas DA D2-like

receptor activation mediates stereotyped behaviors; 7) The
induction of amphetamine-induced locomotor sensitization is

primarily mediated by actions in the ventral tegmental
area, whereas expression of amphetamine-induced behavioral

sensitization is primarily mediated by the nucleus
accumbens; 8) The induction of amphetamine-induced
locomotor sensitization can be blocked by Di-like receptor

antagonism; and 9) Persistence of amphetamine-induced
locomotor sensitization has been shown in mice lacking the
Dia receptor.

When taken together, these findings suggest

the involvement of the DA Di family of receptors in
amphetamine-induced behavioral sensitization.

Hypothesis
Therefore, I proposed that: 1) the DA Di-like receptor

is critically important for the induction and long-term
expression of amphetamine-induced behavioral sensitization,
2) environmental conditibning factors associated with
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amphetamine sensitization are negatively impacted by the

lack of the Dia receptor; and ■3): . 'p

SCH-2339G

would .block amphetamine-induced behavioral- sensitization in

piA-deficient mice>. .indicating that- the Dg receptor is
important for the'occurrence of amphetamipe-induGed
locomotor sensitization.

Experimental Plan

: '

To test.these ideas, .liGonducted three experiments.
In the first experiment, I injected DiA-deficient and wild-

type mice with various doses of amphetamine or saline for
seven consecutive days.

I challenged these mice with .

amphetamine after three and seventeen abstinence days.
This experiment determined whether the DA Dia receptor was

.

responsible for short- and long-term amphetamine-induced
behavioral sensitization. In the second experiment, I

manipulated the conditioning environment. Specifically,



half the DiA-deficient and wild-type mice received

amphetamine in the home cage for seven days and the other

half received amphetamine in the testing chamber for seven

days.

After three abstinence days, I challenged all

animals with amphetamine in the activity chamber.

On the

following day, I challenged all mice with saline to assess ■
conditioned activity.

This experiment determined whether

environmental conditioning factors influenced amphetamineinduced sensitization of DiA-deficient and wild-type mice.
In the third experiment, I injected DiA-deficient and wildtype mice for seven days with varied doses of the Di-like

antagonist SCH-23390 or saline 30-min prior to amphetamine
treatment.

After three abstinence days, I challenged all

animals with amphetamine in the activity chamber.

This

experiment determined whether the DA D5 receptor mediates
amphetamine-induced behavioral sensitization.
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,

GENERAL'METHOD

Subjects

^ -.V- '

Subjects were 271 adult, wild type (+/+) and Dia
deficient (-/-) C57BL-6 mice.

The subjects were bred at

California State University, San Bernardino in a room

maintained at 22-24°C on a 12-hour light/dark cycle.
Litters were culled to a maximum of 12 pups at seven days
of age.

Mice were housed with their dam and sire until 21

days of age after which they were separated by gender until
testing. Care was taken to ensure that a nearly equal

number of male and female mice were assigned to each
treatment group and that no more than one animal from each

litter was placed into any particular group.

Subjects were

conditioned and tested during the light cycle between the
ages of 90 and 120 days.

The Animal Care and Use Committee

at California State University, San Bernardino approved
protocol for the experimental procedures.
Apparatus

1

Behavior was assessed in Coulbourn Instruments, TruScan Photobeam Activity Chambers (25.5 x 25.5 x 41 cm).
chambers were made of Plexiglas and have two sets of 16
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The

pulse-modulated infrared photo beams spaced 1.6 cm apart

with dark gray removable floor trays and an open top.
Drugs 

S(+)-amphetamine sulphate and SCH-23990 (Research
Biochemicals, Natick, MA) were dissolved in saline and

injected intraperitoneally (i.p.) at a volume Of 5 ml/kg.
Statistical Analysis

Repeated measures analyses of variance (ANOVAs) were
used for analyzing the locOmptor activity and stereotyped
sniffing data.

Significant three- and four-way interactions

were further analyzed using lower-order ANOVAs.

Additional

analysis of the data was made using Tukey tests (p < .05).
General Procedure

In each of the three experiments there were seven

conditioning days followed by either one or two challenge

days.

On drug pretreatment days, all animals were given

either amphetamihe or saliner;and then conditioned for 60

min.

On challenge days, all animals were challenged with

either amphetamine or saline to, assess the presence or
absence of behavioral sensitization or conditioned activity.

Length of the testing sessions and number of drug abstinence
days (time between the last drug pretreatment day and the
drug challenge day) varied according to the experiment.
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On all pretreatment and test days, behavioral
assessment took place immediately after amphetamine or

saline treatment.

Locomotor activity was recorded

continuously across the testing session, whereas stereotyped
sniffing was assessed using a fixed interval momentary time

sampling method (Cameron, Crosby, & Crocker, 1988).
Essentially the presence or absence of stereotyped sniffing
was determined in 30-s intervals.

After behavioral

assessment, all animals were immediately placed back in
their home cage and returned to the animal colony room. ;
Genotyping

Di-deficient mice were generated as described in Drago
et al. (1994) from embryonic stem cells, where one of the Di

receptor alleles was targeted in vitro by homologous , ' , ' ,
recombination.

Briefly, a targeting construct containing a

neomycin phosphotransferase gene was inserted into a region
of the Di receptor gene encoding the fifth transmembrane

domain.

A gene sequence (0.75 kb) downstream from the

insertion site was excised.

This excised g

codes for the third intracytoplasmic loop.

sequence :
The insertion of

the targeting construct and the removal of the gene sequence
generates an inactive gene product.
used to create chimeric mice.

Positive clones were

Chimeric males were then

mated to female C57BL-6 mice to create heterozygotes.

Heterozygous mice have one disrupted Di receptor allele,

while Di-deficient mice have both alleles .disruphed;^'^^^^^^^
type mice have two normal Di receptor alleles)

Receptor

binding studies indicate that heterozygous mice have fewer
than half the typical number of striatal Di-like receptors
,(Drago et al., 1994). ,

Despite the reduced number of Di-

like receptors, heterozygous mice tend to respond like wild-

type controls:on behavioral tasks (Drago, Gerfen, Westphal,
Sc Steiner, 1996; Miner et al., 1995).

All mice were genotyped using polymerase chain
reaction (PGR) as described previously (Bender, Drago, & '
Rivkees, 1997; Miner et al., 1995)

The genomic DNA for

the assays was obtained from tail biopsies (done before any
behavioral assessment) and extracted using the PureGene DNA

isolation kit (Gentra Systems, Minneapolis, MN).

Two

independent PGR reactions were performed for genotyping.
The first reaction determined the presence of the neomycin

containing transgene.

This reaction used a forward primer

(D1.5; 5'-ctgattagcgtagcatggactttgtc-3') and a reverse

primer (PGKl; 5'-tggatgtggaatgtgtgcgag-3').

PGR conditions

were 35 cycles of 94°G (20 min), 58°G (20 min), 72°G (1
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m±n) / followed by 72°C (6 min).

PGR products were separated

on a 1.5% agarose gel, with a 330 bp band indicating the
presence of at least one transgenic allele.

The second

reaction determined the presence of the normal Di gene.

It

used a forward primer (JD.27; 5'aaagttccttaagatgtcct-3')
and a reverse primer (JD.26; 5'-tggtggctggaaaacatcaga-3').
PGR conditions were the same as in the first reaction with

the exception that the annealing temperature was 55°G
instead of 58°g.

The presence of a 350 bp band indicated at

least one wild-type allele.
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EXPERIMENT 1

Prior research has indicated that the DA Di family of

receptors are intimately linked to the induction'of
amphetamine sensitization (Bjijou et al., 1996; Crawford et
al., 1997; Vezina, 1996) .,

More specifically, Crawford et

al. (1997) demonstrated that mice lacking the DA Dia receptor
exhibited short-term behavioral sensitization to

amphetamine, however long-term amphetamine sensitization was
not assessed.

Therefore, the purpose of the first

experiment was to determine whether DA DiA-deficient mice
exhibit amphetamine-induced behavioral sensitization after
either a short (3-day) or long (17-day) drug abstinence
period.
Method

Subjects.

Subjects were 92 C57BL-6 DA DiA-deficient and

wild-type mice.

Procedure. The apparatus and procedure described in the
General Methods were used with the following exceptions.

Subjects were injected with amphetamine (1.0, 2.0, 4.0 or
8.0 mg/kg, i.p.) or saline for seven consecutive days. Each
conditioning session lasted for 60 min.

After three

abstinence days, a challenge injection (i.p.) of 1.0 mg/kg
amphetamine or saline was given to all mice to assess the
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occurrence of short-term amphetamine-induced behav-iofal
sensitization.

To assess the .occurrence of long-term

amphetatiine-induced behavioral sensitization, ^ m^^^^

challenged with amphetamine (1.0 mg/kg i.p.) after a 17-day
drug abstinence period.

Locomotor activity and stereotyped

sniffing .were assessed for a total of 150 min.

In summary,

DiA-deficient and wild-type mice received one of the

following six sequences (PRETREATMENT/TEST DAY l/TEST DAY 2)
of amphetamine or saline during the pretreatment phase and
on the first and second test day (doses are in parentheses):
SAL/SAD/AMPH, SAL/AMPH/AMPH-, AMPH(1.0)/AMPH/AMPH,
AMPH(2.0)/AMPH/AMPH, AMPH(4.0)/AMPH/AMPH, or

AMPH(8.0)/AMPH/AMPH.
Results

■

Drug Pretreatment Phase: Locomotor Activity.

Overall,

mice pretreated with 4 or 8 mg/kg amphetamine had larger ,
distance traveled scores than saline controls (see Figure

3) [pretreatment main effect, F(4,82) = 32.57, p < .001;

and Tukey tests, £ < .05].

On all seven pretreatment days,

wild-type and DiA-deficient mice given 4 mg/kg amphetamine,
{filled triangles) exhibited more locomotor activity than

saline-pretreated mice (open circles) [wild-t-ype:
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Figure 3.

Mean distance traveled (+SEM) of adult wild-type and Dja

deficient mice (n = 6 - 10 per group) administered saline (SAL) pr

amphetamine (AMPH; 1.0, 2.0, 4.0, or 8.0 mg/kg, i.p.) for seven
consecutive pretreatment days. Behavioral assessment. las.ted for 60 min

and occurred immediately after injection. O .= .SAL; ® = 1.0 mg/kg
AMPH; ♦ = 2.0 mg/kg AMPH; ▲ = 4.0 mg/kg AMPH; ■ = 8.0 mg/kg AMPH.
* Significantly different from the SAL group , (p <: .05) . ,
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,,

pretreatment x day interaction, F(24,294) = 4.38, £ < .001;
PiA-^deficient: pretreatment x day interaction, F(24,198):

3.79, £ < .001; and Tukey tests, £ < .05].

Wild-type and

Dia"deficient mice pretreated with 8 mg/kg amphetamine
{filled squares) had more distance traveled on time blocks

1 and 2 than saline controls [Tukey tests, £ < .05].
Drug Pretreatment Phase: Stereotyped Sniffing.

During

the pretreatment phase, mice given 8 mg/kg amphetamine
sniffed more than mice given saline (see Figure 4)

: [pretreatment main effect, F(4,82) = 12.06, £ < .001; and

Tukey tests, £ < .05].

This drug effect varied according

to both genotypd and pretreatment day.

On day 1, wild-type

mice pretreated with 4 or 8 mg/kg amphetamine had more
sniffing counts than saline controls; whereas,, wild-type

mice given 2 or 8 mg/kg amphetamine had more sniffing
counts than saline-pretreated mice on day 7 (see upper

graph. Figure 4) [pretreatment x day interaction, F(4,49) =

2.87, £ < .05; and Tukey tests, £ < .05].

DiA-deficient

mice exhibited a different pattern of effects, because only

mice given 8 mg/kg amphetamine sniffed more than salinepretreated mice (see lower graph. Figure 4) [pretreatment
main effect, F(4,33) = 3.36, p < .05; and Tukey tests, £ <
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Figure 4.

Mean stereotypeci sniffing counts (fSElM) of adult wild-type

and DiA-deficient mice (n = 6 , - 10 per group) administered saline ' (SAL) .
or amphetamine (AMPH; 1.Qy 2iO> 4.0, or 8.0 mg/kg, i.p. ) for seven 

consecutive pretreatment days.

Behavibral assessmeht lasted for 60 min

and occurred immediately after injection.

AMPH;; ♦ - 2 .0 mg/kg AMPH;

G ^ SAL; ® = 1.0 itig/kg

= 4 . 0 mg/kg; AMPH; ■

8 : 0 mg/kg AMPH.

*.Sigriifleantly different from the SAL group (p < . 05) .
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Test Day Locomotor Activity: :Three Abstinence Days>

time blocks 1-A, mice pretreated withi4

On

8: mg/kg

amphetamine exhibited more locomotor activity than mice
pretreated with saline (see Fignre 5) [pretreatment; x time
interaction, F(56,910) =5.93, p < .001; and Tukey.tests, p

< .05];

Analyses involving only the wild-type mice showed

that pretreatment with the,two highest doses of amphetamine
(4 and 8 mg/kg) resulted in more locomotor activity on time
blocks 1-4 than saline pretreatment (see upper graph.

Figure 5) [pretreatment x time interaction, F(56,546) =:

5.77, p < .001; and Tukey tests, p < .05].

DiA-deficient

mice exhibited a more complex pattern of drug effects.

For

example, Dia-deficient mice pretreated with 8 mg/kg
amphetamine exhibited more locomotor activity than saline

pretreated mice on time blocks 1 and 2 (see lower graph.
Figure 5) [pretreatment x time interaction, F(56,364) =

1.70, p < .01; and Tukey tests, p < .05].

On the other

hand, DiA-deficient mice pretreated with 4 mg/kg amphetamine
showed enhanced levels of locomotor activity across time

blocks 1-8.

It is important to realize, however, that the

total amount of distance traveled did not vary between
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Figure 5.

Mean ciistanGe traveled (±SEM) of adult wild-type and Dia

deficient mice (n|= 7 - 8 per group) during testing (these are the same
mice as in Figures 1 and 2).

Mice had previously received seven

consecutive injections of saline (SAL) or amphetamine (AMPH; 1.0, 2.0,
4.0, or 8.0 mg/kg, i.p.).

After 3 abstinence days all mice received a

challenge injecticin of AMPH (1.0 mg/kg, i.p.).

Behavioral testing

lasted for 150 min and occurred immediately after injection.

* Significantly different from the SAL group (p < .05).
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wild-type and biA-deficient mice [p > .05].
Test Day Stereotyped Sniffing: Three Abstinence Days.

After a three day abstinence period, amphetamine-pretreated
wild-type and Di^-deficient mice exhibited enhanced

stereotyped sniffing when compared to saline-pretreated
mice (see Figure^6) [pretreatment main effect, F(4,76) =

8.18, p < .001; and Tufcey tests, p< .05].

Specifically,

mice pretreated with 2, 4, or 8 mg/kg amphetamine, and then
challenged with 1 mg/kg amphetamine, had more stereotyped
sniffing counts than mice given amphetamine for the first
time on the test day.

The stereotyped sniffing of wild-

type and DiA-deficient mice did not differ [p > .05].
Test Day Locomotor Activity: Seventeen Abstinence
days.

After 17 drug abstinence days, both wild-type and

DiA-deficient mice showed a sensitized locomotor response :

(see Figure 7) [pretreatment main effect, F(56,770) = 5.57,

p < .001; and Tukey tests, p < .05].

More specifically,

wild-type mice pretreated with 4 or 8 mg/kg amphetamine had
more distance traveled on time blocks 1-3 than saline-

pretreated mice (see upper graph. Figure 7) [pretreatment x

time interaction, F(56,420) = 4.08, p < .001; and Tukey

tests, p < .05].

An almost identical pattern of effects ;
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Figure 6. Mean stereotyped sniffing (±SEM) of adult wild-type and Dia
deficient mice (n= 7 - 8 per group) during testing (these are the same
mice as in Figures /i and 2) . Mice had previously received seven
consecutive injections of amphetamine (AMPH; 1.0, 2.0, 4.0, or 8.0
mg/kg, i.p. ) or saline (SAL) . After 3 abstinence days all mice
received a challenge injection of AMPH (1.0 mg/kg, i.p.) . Behavioral
testing lasted for 150 min and occurred immediately after injection.
* Significantly different from the SAL group (p < .05) .
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Seventeen Abstinence Days
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Figure 1.

Mean distance traveled (±SEM) of adult wild-type and Dia

deficient mice (n- 6 - 7 per group) during the second test day (these
are the same mice as in Figures. 1 and 2) . Mice had previously received
seven consecutive injections of saline (SAL) or amphetamine (T^PH;. 1.0,
2.0, 4.0, or 8.0 mg/kg, i.p.) . After 17 abstinence days ail
received a challenge injection of AMPH (1.0 mg/kg,. i.p. ) . Behavioral

testing lasted for 150 min and occurred immediately after injection.
* Significantly different from the SAL group (p < .05) .
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was shown by Dia-deficient mice, with the only exception

being that the differences between the amphetamine (4 and 8
mg/kg) and "saline-pretreated mice were observed on time
blocks 1 and 2 (see lower graph. Figure 7) [pretreatment x
time interaction, F(55,350) = 2.59, p < .001; and Tukey

tests, p < .05].

The overall locomotor activity of wild-

type and DiA-deficient mice did not differ [p > .05].
Test Day Stereotyped Sniffing: Seventeen Abstinence

Days.

After the extended abstinence period, only mice

pretreated with 2 mg/kg amphetamine exhibited a sensitized
sniffing response on the test day (see Figure 8)

[pretreatment main effect, F(4,59) = 3.44, p < .01; and

Tukey tests, p < .05].

The stereotyped sniffing of wild-

type and DiA-deficient mice did not differ, since the main
effect and interactions involving genotype as a variable
did not reach statistical significance.
Summary

These results indicate that DiA-deficient and wild-type

mice exhibit both short- and long-term behavioral

sensitization after repeated amphetamine treatment.

This

suggests that the DA Dia receptor subtype is not necessary
for amphetamine-induced behavioral sensitization.
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Figure 8. Mean stereotyped sniffing (±SEM) of adult wild-type and Di^
deficient mice (n =6 - 7 per group) during the second test day (these
are the same mice as iri Fighres 1 hhd 2). Mice had previously received
seven consecutive injections of saline (SAL) or amphetamine (AMPH; l.Q/

2.0, 4.0, or 8.0 mg/kg, i.p.).. After 17 abstinence days all mice
received a challenge injectipn of AMPH (1.0 mg/kg,: i.p.). Behavioral
testing lasted for 150 min and;occurred immediately after injectibh.
* Significantly different from the SAL group (p < .05).
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EXPERIMENT 2

; Previous studies have shown that DA Di-like receptors ^
are irnportant for arriphetamine-induced locomotor

sensitization (Bjij[ou et ali,^ 1996; Crawford,et al;, 1997;
Vezina, 1996).

Furthermore, several studies have emphasized

the importance of environmental cues and conditioning
factors for the development of behavioral sensitization

(Badiani et al., 1997; Badiani, Anagnostaras, & Robinson,
1995; Badiani, Browman, & Robinson, 1995). The purpose of

Experiment 2 was to determine whether the DA Dia receptor is
necessary for the environmental conditioning effects
typically observed in amphetamine-induced sensitization.

1

predicted that drug-paired environmental cues enhanced the
amphetamine-induced behavioral sensitization of wild-type,

but not DiA-deficient mice.

This pattern of results would

indicate that the Dia receptor is necessary for environmental
conditioning effects.
Method ■ ;

Iects.

Subjects were 67 male and female C57BL-6 Dia

deficient and wild-type mice
Procedure.

The apparatus and procedure described in

the General Methods were used with the following exceptions,

Animals received either amphetamine (8.0 mg/kg, i.p.) or

saline prior to being placed in the activity chamber.
Behavior was assessed for 6G min.

Prior to being returned

to the home cage, mice were injected with either amphetamine

(8.0 mg/kg, i.p.) or saline.

Specifically, mice injected

with amphetamine prior to being placed in the testing
chamber were injected with saline prior to being returned to

the home cage; whereas, mice injected with salineiprior to
being placed in the testing chamber were injected with
amphetamine prior to being returned to the home cage.
pretreatment phase lasted for seven days.

The

After three

abstinence days, mice were challenged with 1.0 mg/kg
amphetamine in the testing chamber.

Locomotor activity and

stereotyped sniffing were assessed for a total of 150 min.

To assess conditioned activity, all mice were injected
with saline one day after the first test day.

On the second

test day, locomotor activity and stereotyped sniffing were
assessed for 60 min.

In summary, DiA-deficient and wild-type

mice received one of the following three sequences (PRE

POST/TEST DAY l/TEST DAY 2) of drugs during the pretreatment
phase and on the first and second test day (injection
location is in parentheses): SAL(chamber)

SAL(home)/AMPH/SAL, SAL(chamber)-AMPH(home)/AMPH/SAL, or

AMPH(chamber)-SAL(home)/AMPH/SAL.

Results

Locomotor Activity On Test Day 1 (Amphetamine
Challenge): Behavioral Sennitization. , Pretreatment

condition interacted with genotype to affect the locomotor

activity of the mice (see Figure 9) [pretreatment condition
X genotype ■interaction, R (2 , 36) ,= 4 .19, p < .05; and Tukey;
tests, p < .05] .

Wild-type mice exhibited a sensitized

locomotor response, but only if amphetamine pretreatment
was given in the test chamber (see upper graph. Figure 9)

[pretreatment condition x time interaction, F(28,280) =
4.94, p < .001; and Tukey tests, p < .05] .

More

specifically, wild-type mice pretreated with 8 mg/kg
amphetamine in the test chamber {filled squares) , and
challenged with 1 mg/kg amphetamine, exhibited more
locomotor activity on time blocks 1 and 2 than did mice
acutely challenged with amphetamine on the test day {open
circles) .

Wild-type mice pretreated with amphetamine in

the home cage (open squares) did not differ from saline-

pretreated controls (open circles)

[p > .05] .

DxA-deficient mice pretreated with amphetamine in the
test chamber also exhibited more test day locomotor

activity than saline-pretreated mice (see lower graph.
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Figure 9. Mean distan^^^^ traveled (±SEM) of aduit wild-type and
■deficieril:
- 8 per group) during this first test; day. Mice
had preyiously received seven daily injections of saline (SAL) or
amphetamine (AMPH; 8. 0 mg/kg, i.p.) in either their hom^ cage -or iii the
test chamber. ^ A
3 abstinence days all mice received a challenge
ihjectidn of AMPH (1vO mg/kg, i.p.) in the testing chamber. Behavioral

testing lasted for 150:jnih and occurred immediately after;injection::
* Significantly diffeireht from t^

SAL group (p < .05) .
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,

Figure 9) [pretreatment condition x time interaction,

F(28,244) = 1.93, p < .01; and Tukey tests, p < .05].

This

effect was more robust in DiA-deficient mice than with wild-

types, since significant differences:were apparent on time
blocks 1-8.

Unlike wild-type mice, DiA-deficient mice

showed a sensitized locomotor response if amphetamine
pretreatment was given in the home cage [pretreatment

condition main effect, F(2,16) = 7.58, p < .01; and Tukey

tests, p < .05].

Even so, DiA-deficient mice pretreated

with amphetamine in the test chamber {filled squares) had
larger distance traveled scores than DiA-deficient mice

given amphetamine in the home cage {open squares).
Stereotyped Sniffing On Test Day 1 (Amphetamine
Challenge) ; Behavioral Sensitization.

Dia-deficient mice

had significantly more test day sniffing counts than wild-

type controls (see Figure 10) [genotype main effect,
F(l,36) = 5.80, p < .05].

The differences between Dia

deficient and wild-type mice were only observed in those

groups given amphetamine pretreatment (in either the test

chamber or home cage).

Overall, mice given 8 mg/kg

amphetamine in the test chamber had significantly more test
day sniffing counts than saline-pretreated mice, with mice
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Figure 1.0. Mean stereotyped sniffing (±,SEM) of adult wild-type and Dia
deficient mice (n = 6 - 8 per group) ■ during the first test day. Mice ' ;
had previously received seven daily injections of saline (SAEi) or
^
amphetamine (AMPH;; 8.0 mg/kg, i.p.) in either their home cage or in the
test chamber. After 3 abstinende days all mice;received a challenge

injection of AMPH (1.0 mg/kg, i.p.) in the testing cha;mber.

Behavioral

testing lasted for 150 min and occurr^^ immediately after injection.
* Significantly different; from the SAL group (p < ;. 05). > \
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given amphetamine in the home cage being intermediate
[pretreatment condition main effect, F(2,36) = 68.34, p <
.001].

Locomotor Activity On Test Day 2 (Saline Challenge);
Conditioned Activity.

After a challenge injection of

saline, DiA-deficient mice had larger distance traveled

scores than wild-type mice (see Figure 11) [genotype main
effect, F(l,36) = 6.83, p < .05].

The enhanced locomotor

activity exhibited by Dia-deficient mice only occurred in

groups that had been pretreated with amphetamine.

More

specifically, DiA-deficient mice pretreated with 8 mg/kg
amphetamine (in either the home cage or test chamber)
exhibited more locomotor activity than saline-pretreated

mice (see lower graph. Figure 11) [pretreatment condition x

time interaction, F(10,80) =2.14, p < .05; and Tukey

tests, p < .05].

The differences between amphetamine- and

saline-pretreated DiA-deficient mice reached statistical
significance on time blocks 1-4.

In contrast, wild-type

mice pretreated with amphetamine did not show any
conditioned activity (see upper graph. Figure 11).
Stereotyped Sniffing On Test Day 2 (Saline Challenge);
Conditioned Sniffing.

After receiving a challenge
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Figure 11.

Mean distance traveled (iSEM) of adult wild-type and Dia

deficient mice (n = 6 - 8, per group) during the second test day. Mice
had previously received seven daily injections of saline (SAL) or
amphetamine (AMPH; 8.0 mg/kg) in either their home cage or in the test
chamber. After 4 abstinence days all mice received a challenge-

injection of SAL in the testing chamber to assess conditioned activity.
Behavioral testing Tasted for 60 miri and gccurred immediately after the
second injection. * Significantly different from the SAL group (p <
.OS)-. ' '■
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injection of saline, diA-deficient mice sniffed more than

wild-type mide (see Figure 12) [genotype main effect,
F(1,36) = 5.42, p < .05].

The differences hetween the Dia

deficient and wild-type mice were only apparent after

amphetamine pretreatment.

Mice pretreated with 8 mg/kg

amphetamine in the test chamber, but not in the home cage,

had significantly more stereotyped sniffing counts than
saline-pretreated mice [pretreatment condition main effect,
F(2,36) = 14.71, p < .001].

Therefore, both DiA-deficient

and wild-type mice showed conditioned sniffing, but the
effect was more robust in DiA-deficient mice.
Summary

These results indicate that both wild-type and Dxa
deficient mice show more robust behavioral sensitization

when amphetamine is given in the test chamber (i.e.,
Pavlovian associations are allowed to form) than in the

home cage.

Wild-type mice did not show conditioned

activity, whereas DiA-deficient mice showed an exaggerated

locomotor response regardless,of whethe.r amphetamine
pretreatment occurred in the test chamber or home cage.

The latter result suggests that PiA-deficient mice are not
showing true 'conditioned activity', but may only be
showing a generalized hyperactive response caused by
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Test Day 2: Saline Challenge
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Figure 12. Mean stereotyped sniffing counts (±SEM) of adult wild-type
and DiA-deficient mice ,(n = 6 - 8 per giroup) during the second test day.
Mice had previously received seven daily injections,of saline (SAL) or
amphetamine (AMPH; 8.0 mg/kg) in either their home cage or in the test
chamber. After 4 abstinehce days all mice received a challenge
injection of SAL (1.0 mg/kg) in the testing chamber to assess
conditioned sniffing. Behavioral testing lasted for 60 min and
occurred immediately after the second injection. > Significantly
different from the SAL group (p < .05).
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amphetamine pretreatment.
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EXPERIMENT 3

Research has shown that DA Di-like receptors are
necessary for amphetamine-induced sensitization (Bjijou et
al., 1996; Vezina, 1996).

By blocking DA Di-like receptors

with the putative DA Dx-like antagonist SCH-23390, locomotor

activity was reduced to control levels (Bjijou et al., 1996;
Vezina> 1996). However, because the Di-like family of

receptors is composed of two receptors, Dia and Ds, it is
uncertain whether the D5 receptor subtype is necessary for
amphetamine-induced sensitization.

Therefore, in the

present experiment I pretreated DiA-deficient and wild-type

mice with SCH-23390 prior to their daily amphetamine
injections.

I predicted that SCH-23390 pretreatment would

block amphetamine-induced sensitization in DiA-deficient
mice.

The latter result suggested that the D5 receptor is

essential for:behavioral sensitization.
Method

Subjects.

Subjects were 112 male and female C57BL-6 Dia

deficient and wild-type mice.
Procedure.

The apparatus and procedure described in

the General Methods were used with the following exceptions.

Subjects were given a preinjection of SCH-23390 (0.15, 0.5

or 1-5 mg/kg, i.p.) or saline 30 min prior to amphetamine
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(8.0 mg/kg, i.p.) or saline injections. SCH-23390 injections
were given in the home cage, whereas amphetamine was given
prior to placement in the activity chamber.

Behavioral

assessment lasted for 60-min and pccurred on seven

coriseGutive days.

After three abstinence days, mice were

challenged with amphetamine (1.0 mg/kg, i.p.) or saline.
Locomotor activity and stereotyped sniffing were assessed
for a total of 150 min.

In summary, DiA-deficient and wild-type mice received
one of the following nine sequences (ANTAGONIST DRUG

PRETREATMENT DRUG/TEST DAY DRUG) of SCH-23390, amphetamine
or saline during the pretreatment phase and on the test day

(doses are in parentheses): SAL-SAL/SAL, SAL-SAL/AMPH,
SCH(0.15)-SAL/AMPH, SCH(0.5)-SAL/AMPH, SCH(1.5)-SAL/AMPH,
SAL-AMPH/AMPH, SCH(0.15)-AMPH/AMPH, SCH(0.5)-AMPH/AMPH, or
SCH(1.5)-AMPH/AMPH.
Results

, Drug Pretreatment Phase: Locomotor Activity.

During the

drug pretreatment phase Dia-^deficient mice exliiblted more
locomotor activity than wild-type mice [genotype main

effect, F(1,96) = 27.74, p < .001].

The effects of

genotype interacted with pretreatment, since Dia-deficient
mice pretreated with amphetamine had substantially larger
■
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distance traveled scores (M = 150,259 era collapsed across
the seven days) than araphetaraine-pretreated wild-type mice
(M = 41,507 era) [genotype x pretreati^©^ interaction,

F(1,96) = 12.52, p < .001; and Tukey tests, p < .05].

In

addition, Dia-deficient mice pretreated with saline traveled
a greater distance (M =28,834 era) than similarly treated
wild-type mice (M = 7,492 era) [Tukey tests, p < .05],:.

The

effects of genotype and pretreatraent condition varied

according to antagonist (i.e., SCH-23390) treatment, so ■
those effects will be described in the subsequent
subsections.

Amphetamine-pretreated mice.

Amphetamine-pretreated Dia

deficient mice had larger distance traveled scores than , ■

wild-type mice (see Figure 13) [genotype main effect,

F(1,56) = 26.74, p < .001].

Not surprisingly, this effect

varied according to antagonist treatment.

Amphetamine-

pretreated wild-type mice given 0.15 rag/kg SCH-23390
exhibited more locoraotor activity than the 0.5 and 1.5

rag/kg SCH-23390 groups, with,the 0.0 rag/kg group being
intermediate (see upper graph. Figure 13) [antagonist main

effect, F(3,28) = 7.11, p < .001; and Tukey tests, p <
.05].

The differences between the 0.0 rag/kg {open circles)
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Figure 13. Mean distance traveled (±SEM) of adult wild-type and Dia
deficient mice (n = 8 per group) pretreated with saline (SAL) :or the Di-

like antagonist SCH-23390 (SCH; 0.15, 0.5, ori1,5 mg/kg i>pv) fpllowed
by an injection of amphetamine (8.0 mg/kg, i.p. ) 30 min lateri This
injection regimen was admihistered for seven consecutive days.
Behavioral assessment lasted for 60 min and occurred immediately after

the second infection.

* Significantly different from 0. 00 mg/kg SCH

group (p< .05) .
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and 0.5 mg/kg {filled diamonds) SCH-233390 groups reached
statistical significance on pretreatment days 6 and 7 (see

upper graph. Figure 13) [antagonist x day interaction,

F(18,168) = 2.79, p < .001; and Tukey tests, p < .05].
SCH-23390 also affected the locomotor activity of Dia

deficient mice injected with amphetamine.

For example,

amphetamine-pretreated DiA-deficient mice given 0.5 mg/kg
SCH-23390 {filled triangles) exhibited more locomotor

activity than amphetamine-pretreated mice given 0.0 mg/kg
SCH-23390 {open circles) (see lower graph. Figure 13)

[genotype x antagonist interaction, F(3,56) =2.97, p <

.001; and Tukey tests, p < .05].

Amphetamine-pretreated

DiA-deficient mice showed a dose-dependent increase in

locomotor activity as the pretreatment phase progressed

[pretreatment day main effect, F(6,168) = 10.06, p < .001;
and Tukey tests, p < .05].
Saline-pretreated mice.

Saline-pretreated DiA-deficient

mice had larger distance traveled scores than wild-type

mice (see Figure 14) [genotype main effect, F(l,40) =

41.62, p < .001].

This effect varied according to

antagonist treatment.

More specifically, saline-pretreated

wild-type mice given SCH-23390 (0.15, 0.5, or 1.5 mg/kg)
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!Figure'14; Mean distance traveled (±SEM) of adult wild-type and Dia
deficient mice (n = 6 per group) pretreated with saline (SAL) or the Dilike antagonist SCH-2339Q (SC^^ 0.15, 0.5, or 1.5 mg/kg, i.p. ) followed
by an injection of SAL 30 min later. This injection regimen was
administered for seven consecutive days. Behavioral assessment lasted
for 60 min and ocGurred immediately after the second injection.

* Significantly different from 0.00 mg/kg SCH group (p < .05) .
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Mad smaller distance traveled Scores than mice given 0.0

mg/kg SCH-23390 {open circles) (upper graph, Figure 14)
[antagonist main effect, F(3,20) = 10.12, p < .001; and

Tukey tests, p < .05].

Thus, SCH-23390 depressed the

locomotor activity of saline-pretreated wild-type mice.
DiA-deficient mice exhibited a different pattern of drug
effects, since DiA-deficient mice given both saline and 0.15

mg/kg SCH-23390 {filled diamonds) exhibited more locomotor
activity than DiA-deficient mice given saline and 0.0 mg/kg
SCH-23390 {open circles) (see bottom graph. Figure 14).
Due to the large amount of variance, the latter effect only
reached statistical significance on pretreatment day 7

[antagonist x day interaction, F(18,120) = 1.70, p < .05;
and Tukey tests, p < .05].
Drug Pretreatment Phase: Stereotyped Sniffing.

Overall,

DiA-deficient mice had more stereotyped sniffing counts than

wild-type mice during the drug pretreatment phase [genotype
main effect, F(1,96) = 15.11, p < .001].

Not surprisingly,

stereotyped sniffing was most prominent in amphetaminepretreated mice [pretreatment main effect, F(l,96) = 71.08,

p < .001; and Tukey tests, p < .05].
Amphetamine-pfetreated mice.
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0^rerall, amphetamine

pretreated DiA^deficient mice sniffed more than wild-type
controls [genotype main effect, F(1,56) = 14.84;,; p < .001].
It is apparent, however, that, the latter effect;, was

entirely due to the :act

of SCH-23390 (see Figure 15)

[genotype X antagonist interaction, F(3,56) = 3.98, p < .05;
end Tukey tests, p < .05].

Specifically, all doses of SCH

23390 (0.15, 0.5, and 1.5;mg/kg) cku

a significant

reduction in the stereotyped sniffing of amphetamine
,pretreated wild-type mice (see upper graph. Figure 15)

[antagonist main effect, F(3,28) = 38.09, p < .001; and

Tukey tests, p < .05].

In contrast, only 1.5 mg/kg SCH

23390 decreased the stereotyped sniffing of amphetamine-

pretreated DiA-deficient mice (see lower graph, Figure 15)

[antagonist main effect, F(3,28) = 5.38, p < .01; and Tukey
tests, p < .05].
Saline-pretreated mice.

The stereotyped sniffing of

saline-pretreated DiA-deficient and wild-type mice did not

differ (see Figure 16).

Nor was the stereotyped sniffing

of saline-pretreated DiA-deficient and wild-type mice
affected significantly by SCH-23390 pretreatment.
Test Day Locomotor Activity: Amphetamine Pretreatment

Groups.

Genotype interacted with antagonist treatment to
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Figure 15. Mean stereotyped sniffing counts (±SEM) of adult wild-type
and DiA-deficient mice (n = 8 per group) pretreated with saline (SAL) or
the Di-like antagonist SCH-23390 (SCHi 0.15, 0.5, pr 1.5 mg/kg, i.p.)
followed by an injection of amphetamine (8.0 mg/kg, i.pi) 3 0 min later.
This injection regimen was administered for seven consecutive days.
Behavioral assessment lasted for 60 min and .occurred immediately after
the second injection. * Significantly different from; 0.00 mg/kg SCH
group (p < .05) .
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Figure 16.. Mean stereotyped sniffing counts (+SEM) of adult wild-type
and DiK-deficient mice (n =6 per group) pretreated with saline (SAL) or

the Di-like antagonist SCH-23390 (SCH; 0.15, 0.5, or 1.5 mg/kg, i.p.)
followed by an injection of SAL 30 min later. This injection regimen
was administered for seven consecutive days. Behavioral assessment
lasted for 60 min and occurred immediately after the second injection.
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affect the locomotor activity of amphetamine-pretreated

mice (see Figure 17) [genotype x antagonist x time

interaction, F(42,784) = 2.35, p < .001; and Tukey tests, p
< .05].

The locomotor activity of amphetamine-pretreated

wild^type mice was affected by SCH-23390 (see upper graph.

Figure 17) [antagonist x time interaction, F(42,392) = 2.45,

p < .001; and Tukey tests, p < .05].

More specifically,

wild-type mice pretreated with both 0.5 mg/kg SCH-23390 and
amphetamine {filled triangles) exhibited significantly less
locomotor activity on time blocks 1-3 than wild-type mice

given 0.0 mg/kg SGH-23390 and:amphetamine (open oircles).
Thus, a moderate dose of SCH-23390 (0.5 mg/kg) was able to
attenuate the development of amphetamine-induced

sensitization in wild-type mice.

The higher dose of SCH

23390 (1.5 mg/kg) produced a decline in amphetamine-induced
activity, but this did not reach statistical significance.
The locomotor activity of amphetamine-pretreated Dia

deficient mice was not significantly affected by SCH-23390

(see lower graph. Figure 17).

Thus, there is no evidence

that SCH-23390 pretreatment blocked the development of

amphetamine-induced locomotor sensitization in DiA-deficient
mice.
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Figure 17.

Mean distance traveled (±SEM) of adult wild-type and Dia

deficient mice (n = 8 per group) during testing (these are the same
mice as in Figures 11 and 13) . Mice had previously received seven
consecutive injections of either Saline (SAL) or the D^-like antagonist
SCH-23390 (SCH; 0.15, 0.50, or 1.5 mg/kg, i.p.) followed by a second
injection of amphetamine/(is . 0 mg/kg, i.p .) 3 0 min later . After 3

abstinence days all mice received a challenge injection of AMPH (1.0
mg/kg, i.p. ) . Behavioral testing lasted for 150 min and occurred
immediately after second injection. * Significantly different from the
0.0 mg/kg SCH group (p < .05) .
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Test Day Locomotor Activity; Saline Pretreatment Groups.
Genotype and antagonist treatment interacted to affect the

distance traveled scores of saline-pretreated mice (see
Figure 18) [genotype x antagonist interaction, F(3,40) =
5.17, p < .01; and Tukey tests, p < .05].

In wild-type

;

mice, pretreatment with SCH-23390 alone (i.e., no
amphetamine was given during the pretreatment phase)
resulted in enhanced locomotor responding after acute

injection of 1 mg/kg amphetamine on the test day (see upper
graph. Figure 18).

More specifically, wild-type mice

pretreated with both saline and SCH-23390 (0.5 or 1.5

mg/kg) exhibited more test day locomotor activity than mice
pretreated with only saline [antagonist main effect,

F(3,20) = 5.73, p < .001; and Tukey tests, p < .05].

SCH

23390-pretreated DiA-deficient mice showed a similar pattern
of effects, but the results did not reach statistical

significance (see lower graph. Figure 18).

Test Day Stereotyped Sniffing.

Amphetamine pretreatment

produced a robust sensitized sniffing response (see Figure

19).

More specifically, mice pretreated with 8 mg/kg

amphetamine, and challenged with 1 mg/kg amphetamine,
exhibited more stereotyped sniffing than mice acutely
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Figure 18.

Mean distance traveled (±SEM) of adult wild-type and Dia

deficient mice (n = 6 per group) during testing (these are the same
mice as in Figures 12 and 14) . Mice had previously received seven

consecutive injections of either saline (SAL) or the Pi-like antagonist
SCH-23390 (0.15, 0.50, or 1.5 mg/kg, i.p. ) followed by an injection of
SAL 30 min later.

After 3 abstinence days all mice received a

challenge injection of AMPH (1.0 mg/kg, i.p. ) . Behavioral testing
lasted for 150 min and occurred immediately after injection.
* Significantly different from the 0.0 mg/kg SCH group (p < .05) .
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Figure 19. Mean stereotyped sniffing counts (±SEM) of adult wild-type
and DiA-deficient mice (n = 6 - 8 per group) during testing (these are

the same mice as in Figures 11, 12, 13, and 14).

Mice had previously

received seven consecutive injections of either saline (SAL) or the Dilike antagonist SCH-23390 (SCH; 0.15, 0.50, or 1.5 mg/kg, i.p.)
followed by an injection of SAL or amphetamine (8.0 mg/kg, i.p.) 30 min
later. After 3 abstinence days all mice received a challenge injection
of AMPH (1.0 mg/kg, i.p.). Behavioral testing lasted for 150 min and
occurred immediately after injection.
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challenged with amphetamine on the test day [pretreatment

main effect, F(1,96) = 23.26, p < ,001].

Neither genotype

nor SCH-23390 pretreatment affected the overall pattern of
these results [p > .05].
Summary

These results indicate that DiA-deficient mice do not

require stimulation of either member of the Di-like family
of receptors to exhibit amphetamine-induced behavioral

sensitization.

In contrast, wild-type only exhibit

amphetamine-induced behavioral sensitization if the Di-like

receptor system is functional.

76

DISCUSSION

Previous research has indicated that the DA Di-like
family of receptors is important for behavioral

sensitization (Bjijou et al,, 1996; Crawford et al,, 1997;

Vezina, 1996).

The purpose of the present study was to

determine whether a specific member of the Di-like receptor

family, the DA Dia receptor subtype, is necessary for
amphetamine-induced behavioral sensitization.

As

predicted, chronic amphetamine treatment produced a
sensitized behavioral response in wild-type mice.

In fact,

wild-type mice given repeated injections of amphetamine

showed both sensitized locomotor activity and stereotyped
sniffing when tested after 3 and 17 abstinence days (see
Figures 3, 4, 5 and 6).

Importantly, chronic amphetamine

treatment also produced a sensitized locomotor response in
DiA-deficient mice (see lower graphs. Figures 3, 5 and 7).
Although contrary to my original hypotheses, the
latter results are not surprising because Crawford et al.

(1997) have reported that DiA-deficient mice exhibit
amphetamine-induced locomotor sensitization after three

abstinence days.

The present results extend the findings

of the Crawford et al. (1997) study in two important ways.
First, the present study is the first to show that Dia
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deficient mice will exhibit sensitization offa stereotyped
behavior (i.e. ^ .stereotyped sniffing:)

Second/ this is the

first study to show that the sensitized locomotion and

sniffing exhibited by DiA-deficient mice will persist across
an exteiT-d.ed drug abstinence period (i.e., 17 days).
.Therefore,fwhen these results are considered together, it

is apparent that the Dia receptor is not necessary for
either;the short- or.long-term expression of amphetamineinduced behavioral sensitization.

An additional purpose of this study was to determine
whether the associative learning processes involved in
.behavioral sensitization require a functioning Dia receptor

system.

As predicted, wild-type mice pretreated with

amphetamine in the testing chamber exhibited sensitized

locomotor activity and sniffing (see upper graphs. Figures
9 and 10).

Wild-type mice did not exhibit behavioral

sensitization when amphetamine pretreatment occurred in the

home cage.

As with wild-type mice, DiA-deficient mice

showed m.ore robust behavioral sensitization when

amphetamine-pretreatment occurred in the testing chamber;
however, only DiA-deficient mice exhibited sensitized
locomotor activity and sniffing when amphetamine
pretreatment occurred in the home cage (see lower graphs.

Figures 9 and 10)

Therefore, these data suggest that

conditioning factors (i.e., Pavlovian associations) are

:

less important for DiA-deficient mice than for wild-type
controls (i.e., only DiA-deficient mice exhibited behavioral

sensitization when amphetamine was not paired with the test
chamber).

This conclusion is only tentative, since DiA-deficient

mice showed more TObust; c^^^

;cohtrpls. : Spbct^

activity than wild-type

wild-type mice did not exhibit

conditioned activity when saline was administered on the

second test day (see upper graph, Figure 11), and only
exhibited conditioned sniffing when amphetamine
pretreatment was given in the test chamber, but not in the

home cage (see Figure 12).

In contrast, amphetamine-

pretreated DiA-deficient mice showed pronounced conditioned
locomotion and sniffing (see Figures 11 and 12).

This

effect was very complex, however, since conditioned effects

were observed when DiA-deficient mice received amphetamine

in either the home cage or test chamber.

Thus,

amphetamine-pretreated DiA-deficient mice showed
"conditioned" activity and sniffing regardless of whether
amphetamine was actually paired with the testing chamber.
Hence, rather than producing true conditioned activity.

amphetamine pretreatttient in the home cage might simply have
caused an exaggerated responsiveness in Dia-^deficient mid

(i.e., Pavlovian associations may have only been partly

responsible for the increased locomotor activity exhibited
by saline-challenged DiA-deficient mice).
A final goal of this study was to determine whether

the Other member of the Di-like receptor family, the DA D5
receptor subtype, was necessary for amphetamine-induced

behavibral sensitization.

To that jend, wild-type and Dia

deficient mice were given daily pretreatment injeCtiohs of
the Di-like receptor antagonist SCH-23390.

As predicted,

SCH-2339b (0.5 mg/kg) blocked the development of locornotor
sensitization in wild-type mice (see upper graph. Figure
17).

This suggests that the Di family of receptors (either

the Dia or D5 receptor subtype) is important for behavioral
serisitization,

SCH-23390 did not attenuate

the locomotor sensitization exhibited by DxA-deficient mice

(see lower graph. Figure 17).

The most parsimonious

explanation is that neither the Dia nor D5 receptor subtypes
are necessary for the amphetamine-induced locomotor

sensitization of DiA-deficient mice; whereas, Di-like
receptors are necessary for the amphetamine-induced
locomotor sensitization of wild-type controls.
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These finding are novel and suggest many ideas: first,
DiA-receptors may not be important for long-term changes in
behavior (i.e., plasticity); second, Pavlovian associations

may not be as important to DiA-deficient mice as they are for

wild-type mice; third, it is possible that neither Dia nor D5
receptors are important for amphetamine-induced behavioral

sensitization in DiA-deficient mice; fourth, compensatory
mechanisms may be responsible for the amphetamine-induced
behavioral sensitization exhibited by DiA-deficient mice;
and, fifth, the behaviors

locomotor :

activity, sensitized stereotyped sniffing, exaggerated
conditioned activity etc...) exhibited by DiA-deficient mice
may have been influenced by a lack of dynorphin.
DA Dia Receptor Involvement in Amphetamine Sensitization

As previously reported, Dx-like receptor antagonists
block amphetamine- and- cocaine-induced behavioral

sensitization (Bjijou et al., 1996; Kuribara, 1995; Vezina,
1996; Vezina & Stewart, 1989). Therefore, available

evidence suggests that stimulation of Di-like receptors is
necessary for the occurrence of amphetamine-induced
behavioral sensitization.

Yet when DiA-deficient mice were

challenged with amphetamine, a sensitized response
persisted for up to 17 abstinence days.
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That DiA-deficient

mice also showed a sensitized stereotyped sniffing response
is interesting, since Di-like receptor stimulation is

necessary for D2-like mediated behaviors (stereotyped
sniffing often requires a combination of Di-like and D2-like
receptor stimulation) (see Clark & White, 1987, for a

review).

At the very least, it seems clear that the Dxa

receptor is not required to produce stereotyped sniffing in
Dia receptor-deficient mice.
DA D5 Involvement in Amphetamine-Induced Locomotor
SensitizatiOn

Both pretreatment and challenge day data present a

similar picture. That is, SCH-23390 pretreatment blocked
locoTriotor sensitization in wild-type mice> but not Dia

deficient mice (see upper graph. Figure 17).

During the

pretreatment phase, the higher doses of SCH-23390 (0.5 and

1.5 mg/kg) completely blocked amphetamine-induced locomotor
activity of wild-type mice (see upper graph. Figure 13).
This is consistent with the challenge day data, because 0.5

mg/kg SCH-23390; blocked the expression of locbmotdr
sensitization in amphetamine-challenged wild-type mice (see
upper graph. Figure 17).
In contrast, SCH-23390 pretreatment did not block the

amphetamine-induced locomotor activity of Dia-deficient

82 : . ■ ■

mice.:

This pattern of results is aisb consistent; with-

challenge day data, in that SCH-23390 pretreatment was

unable to block the expressioh of amphetamine-induced
locomotor sensitization in DiA-deficient mice (see lower

graph, Figure 17). So, DiA-deficieht and wild-type mice
exhibit distinctly different behavior patterns after
chronic amphetamine treatment. That is, DiA-deficient mice
do not need Dia or D5 receptor stimulation to exhibit

amphetamine-induced locomotor sensitization, whereas wild-

type mice require a functioning Di-like receptor system.
Originally, I hypothesized that if DiA-deficient mice
showed behavioral sensitization, the D5 receptor would play
a necessary role in mediating this effect.

The data do not

support this hypothesis. Instead, it is apparent that Di-

like receptors are necessary for the locomotor
sensitization of wild-type mice, but that neither Dia nor D5
receptors are necessary for the locomotor sensitization of

Dia-deficient mice.

Several explanations may account for

these results. First, SCH-23390 may have, a greater' affinity
for Dia, as opposed to D5 receptors. Thus, SCH-23390 may not

have fully antagonized D5 receptors, perhaps allowing them
to mediate sensitization in DiA-deficient mice. Second,

inherent in recombinant technology is the issue of

corapensation/ In this ca

GGmparisatory.mechariis

may-

have allpvtfed amphetamine-induced behavioral sensitization

to occur in the absence of Di-like receptors.
The Influence of Compensatory Mechanisms in PiA^Peficient
Mice .

The possibility that compensation may allOw Dia
deficient mice to exhibit locomotor sensitization is

particularly interesting, because reports havssugge
role for compensation in several different knockout mice.
For instance, the C57BL-6 mouse strain: includes several

knockout mice, some of which lack the DA transporter, or

the Dxa/ D2, or D4 receptors (Drago, PadungGhaichot,
Domenico, Sc. Fuchs, 1998).

The possibility of compensatory

mechanisms is plausible since Di-like receptbrs have, been
identified early in gestation in normal mice (i.e., during
embryogenesis), leaving the strong possibility that some
compensatory mechanism might have developed by adulthood in

these mice (Clifford et al., 1998; Drago et al., 1998).

Nonetheless, although behavioral data from the present
study strongly suggest the presence of compensatory

mechanisms in Dia-deficient mice, no compensatory mechanisms
(e.g., upregulated D5 receptors, dynorphin levels, changes
in D2-like receptor levels, etc.) have been discovered

(Drago et al., 1998).
D2-Like Receptor Involvement in Plasticity

It is interesting that SCH-23390 pretreatment blocked

the amphetamine-induced sniffing of wild-type mice during

the pretreatment phase, but was ineffective at attenuating
sniffing on the challenge day (see Figures 15 and 19).
These results suggest that the Di-like receptor is necessary
for the occurrence of stereotyped sniffing, but is not

necessary for the eventual expression of a sensitized
sniffing response.

The pretreatment data are consistent

with the idea that Di-like receptor activation is needed for

the occurrence of D2-like receptor-mediated sniffing (Clark
& White, 1987), but the challenge day data make a powerful
statement that Di-like receptor activation may not be

necessary to produce the underlying neurobiological changes
(i.e., plasticity) required for a sensitized sniffing
response.

Conditioned Activity in Wild-Type and PiA-Peficient Mice

One of the more interesting findings of this study was
the robust locomotor activity exhibited by salinechallenged DiA-deficient mice (see lower graph. Figure 11).
Specifically, DiA-deficient mice pretreated with, amphetamine

in either the testing chamber or home cage showed
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substantial amounts pflocqmotot activity after saline
challenge (i.e., more than saline-pretreated rats).

This

effect was not observed in wild-type mice (see upper graph,

Figure 11).,

Because robust locomotor activity was apparent

in DiA-deficient mice pretreated with amphetamine in the

home cage, it appears that non-associative mechanisms,
other than Pavlovian processes, were responsible for this
increased locomotor activity.

One possibility is that a

generalized heightened responsiveness could have caused the
increased locomotion in saline-challenged Dia-deficient
mice.

Thus, rather than showing increased locomotor

activity due to the presence of drug-paired environmental
cues, amphetamine-pretreated DiA-deficient mice may have
only been exhibiting a generalized heightened

responsiveness that would have been expressed in any
environment (see Tirelli & Terry, 1998, for a relevant .

discussion).

Consistent with this idea, DiA-deficient mice

have been described as * hyperactive' in other reports
(Clifford et al., 1998).

Dj-Like Receptor Antagonism: Behavioral Evidence For
Receptor Uprequlation or Supersensitivity

Wild-type mice pretreated with 0.5 or 1.5 mg/kg SCH
23390 alone (i.e., no amphetamine) showed enhanced

■'
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locomotor activity when given an acute injection of

amphetamine on the test day (see upper graph, Figure 18).
The only plausible explanation; for this effect was that
chronic SCH-23390pretreatment caused an upregulation of Di-

like receptors in wild-type mice (see Giorgi, Pibiri, Loi,
& Corda, 1993; O'Boyle, Gavin, & Harrison, 1993).
Accordihg to this idea, a test day injection of amphetamine
had enhanced behavioral impact in SCH-23390-pretreated,

wild-type mice because of the increased number of Di-like
receptors.

Conversely, SCH-23390-pretreated DiA-deficient

mice did not show a significant increase in amphetamineinduced locomotor activity on the test day (see lower
graph. Figure 18), although a nonsignificant trend was
apparent.

Because DiA-deficient mice lack Dia receptors,

only a drug-induced upregulation (or supersensitivity) of D5
receptors could have occurred.

If SCH-23390 pretreatment

did result in an excess number of Ds receptors (or

supersensitiye. D5 receptors) dt was insufficient to

significantly alter the amphetamine-induced locomotor
activity of DiA-deficient mice.
The Role of Dynorphin in PiA-Peficient Mice

K-Opioid receptors are located on the presynaptic
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processes of DA neurons comprising the nigrostriatal and
mesolimbic pathways (see Figure 20) (Hyman, 1996; Steiner &

Gerfen, 1998).

Dynorphin (or the endogemous,ligand of k-

opioid receptors) acts on these presynaptic receptors to
inhibit DA release in both the striatum and nucleus

accumbens (Di Chiara & Imperato, 1988; Spanagel, Herz, &
Shippenberg, 1992; Zaratin & Clarke, 1994).

Importantly,

dynorphin levels are dramatically reduced in DiA-deficient
mice (Xu, Moratalla, Gold, Hiroi, Koob, Graybiel, &

Tonegawa, 1994),• thus DiA-deficient mice may have elevated
basal levels of striatal and accumbal DA.

If true, this

excess DA may be responsible for the heightened

responsiveness exhibited by DiA-deficient mice (see lower
graph. Figure il)>

This heightened responsiveness may have

produced a behavior pattern that mimics behavioral
sehsitization and/or conditioned activity.

Thus, it is

interesting whether amphetamine sensitization would

disappear in DiA-deficient mice if dynorphin was replaced

and/or K-opioid receptors were stimulated.
Since an upregulation of D5 receptors have been
eliminated as a possible form of compensation in Dia
deficient mice (see Figure 18), questions arise whether
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Figure 20.

K-Opioid receptors are located on the presynaptic processes

of DA neurons comprising the nigrostriatal and mesolimbic pathways.
Dynorphin (the endogenous ligand of K-opioid receptors) acts on these
presynaptic receptors to inhibit DA release in both the striatum and
nucleus accumbens. Importantly, dynorphin levels are dramatically
reduced in DiA-deficient mice, thus DiA-deficient mice may have elevated

basal levels of striatal and accumbal DA. If true, this excess DA may
be responsible for the heightened responsiveness exhibited by Dia
deficient mice DYN = Dynorphin; DA = Dopamine; K = K-Opioid receptors;
GABA = y-Amino Butyric Acid; EAA = Excitatory Amino Acid.
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changes in dyndrphin ievel& .may:
compensation.

for this

As mentioned above, it is possible that the ,

lack of dynorphin may act as a compehsatory mechanism in
Dia"deficient mice, allowing these mice to express
amphetamine-induced behavioral sensitization without a

functional Di-like receptor system.

This is important ,

because Di-like receptors have been shown in several reports
to have a central role in amphetamine-induced behaviors, as

well as amphetamine sensitization. In addition, this
proposed compensatory mechanism could be responsible for

the hyperactivity evident in these mice, as well as the ■
heightened display of conditioned activity.

Further

experimentation may reveal how these behaviors were
manifest and what role dynorphin plays in DiA-deficierit
mice.

Summary

When taken together, the results of the present study

provide important evidence about the role of the Di-like

family of receptors in behavioral sensitization.

For

example, neither the Dia nor the D5 receptor is necessary
for amphetamine-induced locomotor sensitization in Dia
deficient mice, but the DA Di-like receptor system is needed
for locomotor sensitization in wild-type mice. DiA-deficient

i'" ' 90 .

mice apparently have a compensatory mechanism, not
involving D5 receptors, that allows the development and
expression of behavioral sensitization.

The sensitization

exhibited by DiA-deficient and wild-type mice is more robust

when drug-paired environmental cues are available (i.e.,

when drug pretreatment and drug challenge occur in the test
chamber).

Interestingly, amphetamine-pretreated Dia

deficient mice, unlike wild-type controls, show a
heightened behavioral responsiveness that is not due to

Pavlovian associations.

Therefore, while both DiA-deficient

and wild-type mice are capable of showing amphetamineinduced behavioral sensitization, these mice exhibit
interesting behavioral differences that are presumably due

to the lack of Dia receptors and/or compensatory mechanisms.
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